Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

BIIB

Biogen Inc

Feb 06 • 04:00PM ET

201.18

+15.82 8.53 %

Healthcare • Drug Manufacturers - General • USA • NASD

Peers: VRTX GILD REGN AMGN MRK PFE BMY LLY JNJ NBIX

| Held by: VTI VOO VO IVV SPY VTV XLV IBB RSP VOE

Scroll to Statements

Index	S&P 500	P/E	22.85	EPS (ttm)	8.81	Insider Own	0.18%	Shs Outstand	146.70M	Perf Week	11.84%
Market Cap	29.51B	Forward P/E	12.82	EPS next Y	15.69	Insider Trans	-0.48%	Shs Float	146.44M	Perf Month	7.63%
Enterprise Value	32.28B	PEG	4.73	EPS next Q	3.38	Inst Own	92.20%	Short Float	3.19%	Perf Quarter	31.12%
Income	1.29B	P/S	3.06	EPS this Y	0.30%	Inst Trans	1.61%	Short Ratio	2.40	Perf Half Y	57.48%
Sales	9.63B	P/B	1.62	EPS next Y	2.38%	ROA	4.50%	Short Interest	4.68M	Perf YTD	14.31%
Book/sh	124.11	P/C	7.73	EPS next 5Y	2.71%	ROE	7.39%	52W High	190.20 5.77%	Perf Year	38.24%
Cash/sh	26.01	P/FCF	12.81	EPS past 3/5Y	-25.04% -18.74%	ROIC	5.21%	52W Low	110.04 82.83%	Perf 3Y	-30.84%
Dividend Est.	-	EV/EBITDA	9.95	Sales past 3/5Y	1.59% -4.35%	Gross Margin	75.04%	Volatility	4.40% 3.38%	Perf 5Y	-28.81%
Dividend TTM	-	EV/Sales	3.35	EPS Y/Y TTM	-21.29%	Oper. Margin	26.00%	ATR (14)	6.00	Perf 10Y	-20.07%
Dividend Ex-Date	-	Quick Ratio	2.03	Sales Y/Y TTM	3.94%	Profit Margin	13.42%	RSI (14)	74.19	Recom	2.34
Dividend Gr. 3/5Y	- -	Current Ratio	2.68	EPS Q/Q	-118.25%	SMA20	13.56%	Beta	0.15	Target Price	197.50
Payout	0.00%	Debt/Eq	0.36	Sales Q/Q	-2.49%	SMA50	13.33%	Rel Volume	1.75	Prev Close	185.36
Employees	7605	LT Debt/Eq	0.36	Earnings	Feb 06 BMO	SMA200	36.49%	Avg Volume	1.95M	Price	201.18
IPO	Sep 17, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	22.45% 3.48%	Trades		Volume	3,404,217	Change	8.53%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Resumed	UBS	Neutral	$185
Dec-10-25	Downgrade	HSBC Securities	Hold → Reduce	$143
Nov-06-25	Upgrade	Stifel	Hold → Buy	$202
Sep-25-25	Initiated	Jefferies	Buy	$190
Jul-21-25	Resumed	Truist	Hold	$142
Apr-28-25	Downgrade	HSBC Securities	Buy → Hold	$118
Apr-04-25	Downgrade	Argus	Buy → Hold
Feb-11-25	Initiated	Bernstein	Mkt Perform	$160
Jan-02-25	Downgrade	Piper Sandler	Overweight → Neutral	$315 → $138
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$230 → $164
Dec-16-24	Downgrade	Stifel	Buy → Hold	$175
Dec-10-24	Resumed	BofA Securities	Neutral	$178
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$250 → $180
Nov-18-24	Downgrade	Needham	Buy → Hold
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-14-24	Initiated	Citigroup	Neutral	$190
Oct-31-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$285 → $204
Oct-10-24	Resumed	Raymond James	Mkt Perform
Feb-14-24	Reiterated	Needham	Buy	$305 → $300
Feb-14-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$315 → $240

Show Previous Ratings

Today 06:09AM	How One Drug Heavy-Lifted Biogen's Fourth-Quarter Beat (Investor's Business Daily) +8.53%
04:02PM	Biogen Inc (BIIB) Q4 2025 Earnings Call Highlights: Strong Growth in Key Products Amidst ... (GuruFocus.com)
03:48PM	Biogen stock pops, Robinhood gets lift as bitcoin ticks up (Yahoo Finance Video)
07:35AM	Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. (Barrons.com)
11:30AM	BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat '26 EPS View (Zacks)
11:15AM	Loading…
11:15AM	Biogen Forecasts 2026 Profit Above Estimates as Shares Climb 30% (GuruFocus.com)
11:12AM	Pre-Markets Open in Green to Close the Week (Zacks)
10:33AM	Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump (Benzinga)
10:29AM	Pre-Markets Rebounding Ahead of Super Bowl Sunday (Zacks)
10:10AM	Biogen Q4 Earnings Call Highlights (MarketBeat)
09:42AM	Stock Market Today: Dow Rallies, Bitcoin Bounces; Amazon Dives On Earnings Results (Live Coverage) (Investor's Business Daily)
09:30AM	Biogen (BIIB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:59AM	Biogen Revenue Down as Multiple Sclerosis Sales Slide (The Wall Street Journal)
08:59AM	Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide (The Wall Street Journal)
07:17AM	Biogen's (NASDAQ:BIIB) Q4 CY2025: Strong Sales (StockStory)
07:15AM	Loading…
07:15AM	Biogen Inc. (BIIB) Q4 Earnings and Revenues Top Estimates (Zacks)
07:03AM	Biogen shares rise as Q4 earnings beat expectations, 2026 profit outlook strong (Investing.com)
05:39AM	Consumer Sentiment, Biogen Earnings: What to Watch Friday (The Wall Street Journal)
05:35AM	Stocks to Watch Friday: Amazon, Roblox, Stellantis, Strategy (The Wall Street Journal)
Feb-05-26 07:00PM	Under Armour earnings, Fed, Liftoff Mobile IPO: What to Watch (Yahoo Finance Video)
04:27AM	Amazon and Biogen Earnings: Still to Watch This Week (The Wall Street Journal)
Feb-04-26 10:02PM	Biogen (BIIB) Reports Q4: Everything You Need To Know Ahead Of Earnings (StockStory)
04:01PM	Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (Business Wire)
07:30AM	Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy (GlobeNewswire)
04:36AM	Big Tech and Pharma Earnings: What to Watch This Week (The Wall Street Journal)
Feb-03-26 02:57PM	These Are The Worst 25 Stocks to Own in February (Schaeffer's Research)
10:00AM	Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
07:56AM	New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings (Zacks)
Feb-01-26 07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
Jan-30-26 10:00AM	Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for (Zacks)
04:09PM	Loading…
Jan-29-26 04:09PM	Phillip Allen Sharp Improved Human Health With Breakthroughs (Investor's Business Daily)
08:53AM	Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status (Zacks)
06:06AM	FDA grants breakthrough status to Biogen's litifilimab for CLE (Pharmaceutical Business Review)
Jan-28-26 12:47PM	Pharma Stocks Are Close to 'Breaking Out.' Earnings Could Set Them Free. (Barrons.com)
07:30AM	Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options (GlobeNewswire)
Jan-25-26 06:30PM	FDA Accepts LEQEMBI IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review (PR Newswire)
06:30PM	FDA Accepts LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review (GlobeNewswire)
Jan-22-26 09:00AM	Investors load Corxel with $287M for a differentiated obesity pill (BioPharma Dive)
Jan-20-26 08:28AM	3 Biotech Stocks That Look Like "Sure-Fire" Winners in 2026 (MarketBeat)
Jan-14-26 08:46AM	What to Expect From Biogen's Next Quarterly Earnings Report (Barchart) -5.04%
Jan-13-26 11:45AM	JPM26: Biotechs M&A lift, the new Biogen and Mercks $70B target (BioPharma Dive)
09:11AM	Biogen CEO Chris Viehbacher on 2026 drug pipeline outlook, rare disease strategy (CNBC TV)
03:02AM	Biogen CEO Says New Drugs Offset MS Decline, Eyes 2026 Transformational Era at JPMorgan Conference (MarketBeat)
Jan-12-26 11:05AM	Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA (nusinersen) for Spinal Muscular Atrophy (GlobeNewswire)
Jan-11-26 11:05PM	3 Reasons to Sell BIIB and 1 Stock to Buy Instead (StockStory)
02:00PM	Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome (Business Wire)
Jan-10-26 02:57PM	Here's What Analysts Think About Biogen Inc. (BIIB) (Insider Monkey)
Jan-07-26 01:01PM	Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up (Zacks)
Jan-05-26 08:00PM	Biologics License Application for Subcutaneous Formulation of "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China (GlobeNewswire)
01:52PM	Biotech and Pharma Stocks Tumble as Investors Race into Energy (Barrons.com)
07:02AM	Samsung Bioepis initiates Byooviz commercialisation in Europe (Pharmaceutical Business Review)
Jan-02-26 07:44AM	Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth (Zacks)
Dec-29-25 10:03AM	UnitedHealth Works Toward Recovery and 4 More Healthcare Themes to Watch in 2026 (Barrons.com)
Dec-28-25 03:00AM	5 Healthcare Themes for Investors to Watch in 2026 (Barrons.com)
Dec-22-25 11:20AM	The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS (GlobeNewswire)
Dec-21-25 10:31PM	Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers (StockStory)
Dec-19-25 11:50AM	Biogen (BIIB) Stock Trades Up, Here Is Why (StockStory)
Dec-17-25 05:13PM	HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress (Insider Monkey)
01:40PM	MicroStrategy Gets to Stay in the Nasdaq-100. Does It Deserve to Stay in Your Portfolio Too? (Barchart)
Dec-16-25 01:15PM	Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117% (Investor's Business Daily)
Dec-15-25 12:15PM	MicroStrategy retains place in key index despite delisting threats (TheStreet)
10:05AM	Lululemon Set to Exit Nasdaq 100 as Index Adds New Members (GuruFocus.com)
09:11AM	Western Digital stock rises after inclusion in Nasdaq-100 Index (Investing.com)
07:03AM	200% Surge? These 6 Stocks Just Crashed the Nasdaq 100 Party (GuruFocus.com)
Dec-13-25 11:04AM	Walmart was too late for a Nasdaq-100 spot - but these 6 stocks made the cut (MarketWatch)
Dec-12-25 08:21PM	Bitcoin hoarding company Strategy remains in Nasdaq 100 (Reuters)
04:53AM	Analysts flag risks for Strategy at Nasdaq 100 index reshuffle (Reuters)
Dec-10-25 11:31PM	3 Healthcare Stocks We Think Twice About (StockStory)
12:40PM	ASH 2025: AbbVie and Genmabs Epkinly sets new standard in second-line FL (Clinical Trials Arena)
11:13AM	Fed Cuts Rates for Third Time This Year, Signals One More in 2026 (Barchart)
09:40AM	Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls (The Fly)
09:09AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More (24/7 Wall St.)
08:36AM	HSBC highlights one pharma stock to buy and one to sell for 2026 (Investing.com)
04:47AM	Health Canada approves Biogen's Zurzuvae for PPD treatment (Pharmaceutical Business Review)
Dec-08-25 06:30PM	"LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List (GlobeNewswire)
01:53PM	Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business? (Zacks)
03:37AM	Is Biogen Stock Outperforming the Dow? (Barchart)
Dec-05-25 11:30AM	Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue? (Zacks)
09:56AM	Denali Enters Into a $275M Funding Deal With Royalty Pharma (Zacks)
09:00AM	Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting (GlobeNewswire)
Dec-03-25 06:10PM	Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 (GlobeNewswire)
11:30AM	Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report? (Zacks)
07:26AM	Tech Is Getting Left Behind in the S&P 500s Latest Rebound (Bloomberg)
Dec-02-25 04:40PM	New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI (lecanemab-irmb) on Neurotoxic Aß Protofibrils in CSF (PR Newswire)
Dec-01-25 07:30AM	Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting (Business Wire)
07:30AM	Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting (GlobeNewswire)
Nov-27-25 07:30PM	Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI" for the Treatment of Early Alzheimer's Disease in Japan (GlobeNewswire)
Nov-26-25 05:30AM	Hedge Funds Pile Into Health Stocks Leading Market in Rotation (Bloomberg)
Nov-25-25 12:28PM	FDA Decision Opens Bigger Market for Novartis's Blockbuster Gene Therapy (Barrons.com)
10:43AM	Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline (Zacks)
07:30AM	Eisai Completes Rolling Submission to US FDA for LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status (GlobeNewswire)
Nov-24-25 04:33PM	Novo Dives After Weight-Loss Pill Fails In Alzheimer's Disease; Biogen Jumps (Investor's Business Daily)
11:46AM	Novo's $5 Billion Alzheimer's Dream Just Died--And Investors Are Cratering the Stock (GuruFocus.com)
11:35AM	Stock Market Today: Dow, Nasdaq Up As This Stock Tests Entry; Health Plays Pop (Live Coverage) (Investor's Business Daily)
11:34AM	Novo Nordisk Stock Falls. Why Its Alzheimer's Trial News Is Hitting Shares. (Barrons.com)
10:40AM	Novo Nordisks Alzheimers Trials Were a Long Shot. Their Failure Is Still Hitting the Stock. (Barrons.com)
10:26AM	Stock Market Today: Dow Jones Rises, Techs Jump; Google Pops On Salesforce Praise, Novo Nordisk Dives (Investor's Business Daily)
09:22AM	Biogen to gain from Novo Nordisk Alzheimers failure, says Jefferies (Investing.com)
07:30AM	Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions (GlobeNewswire)
07:25AM	Novo Nordisk Stock Falls After Ozempic Fails to Slow Alzheimer's in Trials. Biogen Jumps. (Barrons.com)

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Singhal Priya	Head of Development	Jan 30 '26	Option Exercise	0.00	1,829	0	7,601	Feb 03 05:17 PM
Singhal Priya	Head of Development	Feb 02 '26	Sale	179.30	748	134,116	6,271	Feb 03 05:17 PM
Singhal Priya	Officer	Feb 02 '26	Proposed Sale	179.30	748	134,116		Feb 02 11:10 AM
Viehbacher Christopher	President and CEO	Dec 01 '25	Option Exercise	0.00	7,040	0	19,847	Dec 03 04:42 PM
Grogan Jane	Head of Research	Oct 31 '25	Option Exercise	0.00	695	0	2,128	Nov 04 04:12 PM
Godbout Sean	Chief Accounting Officer	Oct 02 '25	Option Exercise	0.00	26	0	503	Oct 06 01:00 PM
Singhal Priya	Head of Development	Aug 29 '25	Option Exercise	0.00	1,669	0	7,096	Sep 02 05:56 PM
Singhal Priya	Head of Development	Sep 02 '25	Sale	133.55	517	69,045	5,772	Sep 02 05:56 PM
Singhal Priya	Officer	Sep 02 '25	Proposed Sale	133.55	517	69,045		Sep 02 12:54 PM
Izzar Rachid	Head of Global Product Strat.	Jul 08 '25	Sale	135.00	2,223	300,105	6,330	Jul 16 05:55 PM
Izzar Rachid	Officer	Jul 08 '25	Proposed Sale	135.00	2,223	300,105		Jul 08 03:26 PM
Singhal Priya	Head of Development	May 19 '25	Sale	126.25	3,806	480,508	5,427	May 20 04:05 PM
Singhal Priya	Officer	May 19 '25	Proposed Sale	126.25	3,806	480,508		May 19 11:24 AM
Keeney Adam	Head of Corporate Development	May 01 '25	Option Exercise	0.00	938	0	2,838	May 05 04:19 PM
DORSA CAROLINE	Director	May 02 '25	Buy	122.72	1,235	151,559	27,842	May 05 04:17 PM
SHERWIN STEPHEN A	Director	Mar 07 '25	Sale	150.02	8,760	1,314,142	11,318	Mar 10 04:09 PM
STEPHEN A SHERWIN	Director	Mar 07 '25	Proposed Sale	147.37	8,760	1,290,961		Mar 07 04:18 PM
Singhal Priya	Head of Development	Feb 10 '25	Option Exercise	0.00	1,212	0	9,423	Feb 12 05:48 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 10 '25	Option Exercise	0.00	2,272	0	14,725	Feb 12 05:47 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 10 '25	Option Exercise	0.00	3,257	0	25,712	Feb 12 05:46 PM
Kramer Robin	Chief Accounting Officer	Feb 10 '25	Option Exercise	0.00	834	0	8,257	Feb 12 05:44 PM
Gregory Ginger	EVP, Human Resources	Feb 10 '25	Option Exercise	0.00	2,159	0	18,232	Feb 12 05:43 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 10 '25	Option Exercise	0.00	2,575	0	37,072	Feb 12 05:42 PM
Izzar Rachid	Head of Global Product Strat.	Feb 10 '25	Option Exercise	0.00	1,515	0	8,998	Feb 12 05:40 PM
Izzar Rachid	Head of Global Product Strat.	Feb 07 '25	Option Exercise	0.00	3,844	0	7,860	Feb 11 09:52 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 07 '25	Option Exercise	0.00	4,551	0	23,171	Feb 10 06:59 PM
Viehbacher Christopher	President and CEO	Feb 07 '25	Option Exercise	0.00	9,008	0	16,008	Feb 10 06:55 PM
Grogan Jane	Head of Research	Feb 07 '25	Option Exercise	0.00	1,385	0	1,876	Feb 10 06:52 PM
Keeney Adam	Head of Corporate Development	Feb 07 '25	Option Exercise	0.00	1,801	0	2,463	Feb 10 06:51 PM
Kramer Robin	Chief Accounting Officer	Feb 07 '25	Option Exercise	0.00	1,491	0	7,667	Feb 10 06:48 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 07 '25	Option Exercise	0.00	4,042	0	13,056	Feb 10 06:47 PM
Singhal Priya	Head of Development	Feb 07 '25	Option Exercise	0.00	2,216	0	8,892	Feb 10 06:45 PM
Gregory Ginger	EVP, Human Resources	Feb 07 '25	Option Exercise	0.00	3,436	0	16,633	Feb 10 06:44 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 07 '25	Option Exercise	0.00	4,130	0	35,088	Feb 10 06:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BIIB

Biogen Inc

Upgrade your FINVIZ experience